{"id":"placebo-to-match-hydroxycarbamide","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL6068498","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo-to-match products are inert formulations engineered to be indistinguishable from the active drug in terms of appearance, taste, smell, and administration route. In this case, it mimics hydroxycarbamide (hydroxyurea) to serve as a control arm in Phase 3 trials, allowing for blinded comparison of the active drug's efficacy and safety against an inert comparator.","oneSentence":"This is a placebo formulation designed to match the appearance and administration of hydroxycarbamide for use as a control in clinical trials.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:43.243Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in Phase 3 clinical trials (indication depends on the active hydroxycarbamide trial)"}]},"trialDetails":[{"nctId":"NCT01389024","phase":"PHASE2","title":"Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2012-08-16","conditions":"Sickle Cell Disease, Stroke","enrollment":28},{"nctId":"NCT04617028","phase":"PHASE3","title":"Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis","status":"COMPLETED","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","startDate":"2021-02-05","conditions":"Myelofibrosis","enrollment":105},{"nctId":"NCT00568698","phase":"PHASE1, PHASE2","title":"A Pilot Therapeutic Trial Using Hydroxyurea in Type I Spinal Muscular Atrophy Patients","status":"COMPLETED","sponsor":"Stanford University","startDate":"2004-01","conditions":"Muscular Atrophy, Spinal","enrollment":29},{"nctId":"NCT00568802","phase":"PHASE1, PHASE2","title":"A Pilot Therapeutic Trial Using Hydroxyurea in Type II and Type III Spinal Muscular Atrophy Patients","status":"COMPLETED","sponsor":"Stanford University","startDate":"2004-01","conditions":"Muscular Atrophy, Spinal","enrollment":27}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to match Hydroxycarbamide","genericName":"Placebo to match Hydroxycarbamide","companyName":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","companyId":"suzhou-zelgen-biopharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo formulation designed to match the appearance and administration of hydroxycarbamide for use as a control in clinical trials. Used for Control arm in Phase 3 clinical trials (indication depends on the active hydroxycarbamide trial).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}